Wacker Biosolutions to focus on biotechnology

Published: 2-Mar-2010
Manufacturing Ingredients Finance Pharmaceutical

Wacker Fine Chemicals becomes Wacker Biosolutions and concentrates on biotechnology

Wacker, the German chemical company, has changed the name of its Wacker Fine Chemicals division to Wacker Biosolutions as it gives the business a biotechnology focus.

Wacker Biosolutions will concentrate on building its business in three main areas, including pharmaceuticals, alongside its existing portfolio of fine chemicals and chemical intermediates. Its biotech products include cyclodextrins, cysteine and biologics, as well as fine chemicals and PVAc solid resins.

The Munich-based firm is currently extending process development and production capacities for the manufacture of pharmaceutical proteins at Wacker Biotech in Jena, Germany.

Wacker aims to offer tailored complete solutions to customers, taking advantage of the synergies between its chemical and biotech expertise. It sees potential in providing innovative products and technologies in the budding market for bioengineered products.

"This reorganisation lays further foundations for Wacker's future success in the growing field of biotechnology," said Gerhard Schmid, senior vice president of Wacker Biosolutions.

Over the past few years, Wacker has posted high double-digit growth with biotech products such as cyclodextrins and cysteine. The group sees future global-market potential in pharmaceutical actives, food additives and agrochemicals.

See more

You may also like

Manufacturing

Pioneering Peptide-Builder debuts at UEA

Read more
Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich

Trending Articles

  1. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  2. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  3. Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma Executive with over 20 years of management experience to lead pharmaceutical packaging and delivery systems company
  4. Abzena and Mabqi announce strategic partnership to offer integrated discovery through development solution This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution

You may also like

Manufacturing

Pioneering Peptide-Builder debuts at UEA

Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich
Finance

hVIVO’s CRS secures more than £5m in early-phase clinical trial contracts to strengthen 2026 pipeline

hVIVO’s German subsidiary CRS has signed more than £5 million in early-phase clinical trial contracts across cardiometabolic, dermatology, infectious disease, renal and oncology, bolstering its 2026 orderbook and highlighting the growing cross-selling benefits across the Group
Manufacturing

Moderna invests $140m to onshore drug product manufacturing and complete US end-to-end mRNA network

Moderna is expanding its Norwood, Massachusetts site to bring drug product manufacturing in-house, creating hundreds of biomanufacturing jobs and establishing full domestic, end-to-end production for its mRNA vaccines and therapeutics by 2027
Manufacturing

GEA to showcase Rockwell Automation-Compatible GEA kytero 2000 Single-Use Separator at Automation Fair 2025

As a gold-level OEM member of the Rockwell PartnerNetwork™, GEA is strengthening its collaboration with Rockwell by offering full compatibility between the kytero® 2000 and Rockwell’s latest hardware and software suite
Manufacturing

SU Puresonic ultrasonic sensor ensures precise hygienic flow measurement

Innovative design meets the highest standards in food, pharma, and water treatment
Finance

Sofinnova Partners closes €650m ($750m) Capital XI fund to boost early-stage biotech investment across Europe and the US

Sofinnova Partners has closed its flagship Capital XI fund at €650m, surpassing its target. The Paris-based firm will use the fund to advance early-stage biotech and medtech companies in Europe and North America
Finance

Johnson & Johnson to acquire Halda Therapeutics for $3.05bn, expanding US oncology drug pipeline

Johnson & Johnson has agreed to acquire Connecticut-based Halda Therapeutics for $3.05bn. The deal strengthens its oncology portfolio, including Halda’s first-in-class RIPTAC therapy for advanced prostate cancer
Subscribe now